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ARTICLE
First-Pass CYP3A-Mediated Metabolism of Midazolam in
the Gut Wall and Liver in Preterm Neonates
Janneke M. Brussee 1, Huixin Yu1, Elke H. J. Krekels 1, Berend de Roos1, Margreke J. E. Brill2,
Johannes N. van den Anker3,4,5, Amin Rostami-Hodjegan6,7, Saskia N. de Wildt3,8 and Catherijne A. J. Knibbe1,9*
To predict first-pass and systemic cytochrome P450 (CYP) 3A-mediated metabolism of midazolam in preterm neonates, a
physiological population pharmacokinetic model was developed describing intestinal and hepatic midazolam clearance in
preterm infants. On the basis of midazolam and 1-OH-midazolam concentrations from 37 preterm neonates (gestational age
26–34 weeks) receiving midazolam orally and/or via a 30-minute intravenous infusion, intrinsic clearance in the gut wall and
liver were found to be very low, with lower values in the gut wall (0.0196 and 6.7 L/h, respectively). This results in a highly
variable and high total oral bioavailability of 92.1% (range, 67–95%) in preterm neonates, whereas this is around 30% in adults.
This approach in which intestinal and hepatic clearance were separately estimated shows that the high bioavailability in
preterm neonates is explained by, likely age-related, low CYP3A activity in the liver and even lower CYP3A activity in the gut
wall.
CPT Pharmacometrics Syst. Pharmacol. (2018) 7, 374–383; doi:10.1002/psp4.12295; published online 10 May 2018.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 That the CYP enzymes are present in the gut wall
and liver, but a different contribution of the gut and the
liver to the first-pass effect may be anticipated in chil-
dren as compared with adults, due to different rates of
maturation of intestinal and hepatic enzymes in infants
and children.
WHAT QUESTION DID THIS STUDY ADDRESS?
 That first-pass metabolism in the gut wall and liver
can be predicted for the CYP3A substrate midazolam
using a state-of-the-art physiological population PK
modeling approach.
WHAT DOES THIS STUDY ADD TO OUR
KNOWLEDGE?
 A very low first-pass effect by intestinal and hepatic
CYP3A-mediated metabolism was found for midazolam
in preterm neonates, yielding much higher bioavailabil-
ity of midazolam in preterm neonates compared with
adults. Furthermore, intestinal CYP3A activity, repre-
sented by intrinsic clearance in the gut wall, was much
lower than hepatic CYP3A activity, represented by the
intrinsic clearance in the liver.
HOW MIGHT THIS CHANGE DRUG DISCOVERY,
DEVELOPMENT, AND/OR THERAPEUTICS?
 Characterization of gut wall and hepatic CYP3A
activity enables quantitative predictions of first-pass
and systemic metabolism of midazolam and potentially
other CYP3A substrates in preterm neonates.
The neonatal body is undergoing many dynamic changes
in the first months of life,1 with preterm neonates showing
delayed maturation of many organs as compared with term
neonates. This results among others in an altered and
highly variable capacity to deal with xenobiotics, including
drugs.2,3 Metabolic capacity is an important determinant
for the bioavailability and systemic clearance of drugs that
are subject to metabolic clearance. Bioavailability impacted
by intestinal and hepatic metabolism and systemic clear-
ance impacted by hepatic metabolism are the two main
drivers of drug exposure. Interindividual differences in
these two parameters are, therefore, two of the main
drivers of differences in drug dose requirements between
patients.
Physiological parameters that affect drug metabolism
include protein binding, blood flow, and intrinsic clearance,
the latter of which represents metabolic capacity.3,4 Devel-
opmental changes in albumin concentrations5 and drug pro-
tein binding6 have been reported in neonates, as well as
changes in cardiac output,5 which influence the intestinal
and hepatic blood flow.7 However, there is limited knowl-
edge on the development of intrinsic clearance of many
drugs, especially with respect to the intestinal and hepatic
enzyme activity in preterm infants.
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Cytochrome P450 (CYP) is an enzyme family involved in
drug metabolism and its ontogeny in children has been stud-
ied both in vitro and in vivo.8 The CYP3A subfamily (i.e.,
CYP3A4, CYP3A5, and CYP3A7) is involved in metabolism
of many clinical important drugs with midazolam commonly
used as a probe drug to reflect combined CYP3A activity.9,10
Midazolam is a benzodiazepine, often used for sedation in the
neonatal intensive care unit,11 and its CYP3A-mediated clear-
ance have been reported to be lower in neonates, infants,
and children, compared with adults.12 As CYP3A resides in
both the gut wall and the liver,13 it is of interest to distinguish
between intestinal and hepatic CYP3A activity with respect to
their roles in first-pass metabolism, particularly because intes-
tinal and hepatic enzymes may mature at different rates.
Besides CYP3A activity in the gut wall and liver, important
factors that may affect the absorption and metabolism of
drugs in the gut wall are among others the intestinal surface
area and the permeability of the endothelium.14 Preterm
infants have a smaller surface area and are known to have
an underdeveloped intestinal barrier,15 resulting in a higher
intestinal permeability in neonates with gestational ages of
<34 weeks.16
To describe and predict pharmacokinetic (PK) profiles and
drug exposure in patients, different types of models have
been used based on availability of data and their purpose.
These models range from relatively simple, empirical models,
to more complex (semi-)physiologically based PK models.17
Empirical models often lack predictive value outside the stud-
ied population, whereas large physiologically based pharma-
cokinetic models are not always identifiable and may depend
on system parameters that are difficult to determine experi-
mentally in children. Therefore, a hybrid of these models is
useful not only to determine PK of a single drug but also to
obtain insight into drug independent systems information
when the models are used for several drugs simultaneously.18
In this analysis, we used a physiological population PK model-
ing approach, in which we account for the attributes of the
gastrointestinal tract and use available systems data together
with PK information from the preterm population to describe
intestinal and hepatic midazolam clearance and ultimately pre-
dict first-pass and systemic metabolism by CYP3A of midazo-
lam in preterm neonates.
METHODS
Data
Thirty-seven preterm neonates (gestational ages ranging from
26–34 weeks, birth weights 745–2,135 grams) of a previously
published dataset from the neonatal intensive care unit of the
Sophia’s Children Hospital in Rotterdam were included.19,20 At
the time of the clinical investigation, their postnatal ages
ranged from 3–11 days and their body weights between 770
and 2,030 grams. These infants were randomly assigned to
receive 0.1 mg/kg midazolam orally via a nasogastric tube
(n5 13) or intravenously via a 30-minute infusion (n525). If,
after 72 hours, the participating infants still met the inclusion
criteria, they received another dose of midazolam but this
time via the other route. Midazolam and its primary metabolite
1-OH-midazolam were measured in plasma 0.5, 1, 2, 4, 6,
12, and 24 hours postdose19,20 and measurements below the
lower limit of quantification were discarded (<1% and <2% of
329 and 153 midazolam and 1-OH-midazolam measure-
ments, respectively).
Model development
Structural physiological pharmacokinetic model. Physiologi-
cal population PK modeling was performed using first-order
conditional estimation with interaction in NONMEM version
7.3 (ICON, Globomax, Ellicott, MD) with Pirana 2.9.0 and R
(version 3.3.1) and R-studio (version 0.98.1078) for proc-
essing of the runs and visualization of data.
A physiological population PK model, earlier described by
Yang et al.,21 Frechen et al.,22 and Brill et al.,23 was applied
to describe the data (Figure 1). For this, using the blood:
plasma ratio and the measured molar concentrations in
plasma, the drug and metabolite molar concentrations in
blood were calculated to be able to be used in the well-
stirred model. The model describes physiological compart-
ments representing the gut wall, the portal vein, and the
liver, and an empirical central compartment for midazolam
and 1-OH-midazolam, representing the blood circulation
and equilibrating tissue.21,22 For midazolam and 1-OH-
midazolam, also the addition of empirical peripheral compart-
ments was evaluated. The fraction of midazolam metabo-
lized into 1-OH-midazolam was assumed to be 1.
Tissue volumes for the physiological compartments in the
preterm neonatal population were allometrically scaled from
tissue volumes of a term neonate7 with a fixed exponent
of 1 (Table 1 5–7,24–31,48). Volume of the portal vein was
assumed to be 77.8% of the hepatic volume.24 The hepatic
blood flow was assumed to allometrically scale from a term
neonate7 with a fixed exponent of 0.75. Blood flows in the
other tissues were assumed to be proportional to the
hepatic blood flow (Table 15,7,25,32).
The well-stirred model was used to quantify the hepatic
extraction of midazolam (EH) and 1-OH-midazolam (EH,M):
EH5
CLint;H3fu;B
Qh1 CLint;H3fu;B
  (1)
where CLint,H is the estimated intrinsic clearance in the liver
based on unbound blood concentrations, fu,B is the fraction
unbound drug concentration in blood, and Qh is the hepatic
blood flow.
For gut wall metabolism into 1-OH-midazolam (EG), the
Qgut model was applied
25:
EG5
CLint;G3fu;G
Qgut1 CLint;G3fu;G
  (2)
where CLint,G is the estimated intrinsic clearance in the gut
wall based on unbound concentrations, fu,G is the fraction
unbound drug concentration in the gut wall, and Qgut is the
local blood flow, which is defined by25:
Qgut5
Qvilli3CLperm
Qvill i1CLperm
(3)
where Qvilli is the villous blood flow and CLperm is the per-
meability of the drug through the enterocytes in the gut
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wall, which depends on the effective intestinal permeability
per unit surface area25 and the intestinal surface area. The
intestinal surface area (A) was calculated based on the net
cylindrical surface area of the small intestine using Eq. 4.
A5 2p3r3h (4)
in which r is the intestinal radius of 1 cm,26 and h the intes-
tinal length of 2.736 3 (WT[g])0.512 cm.27 The fraction
unbound in the gut (fu,G) for both midazolam and 1-OH-
midazolam was assumed 1.25 The absorption rate constant
could not be estimated and was assumed to be 10 h21,
which entails an expected maximum concentration around
12.5 minutes (time of maximum plasma concentration
(Tmax)). A sensitivity analysis was performed with values for
ka ranging from 4.16–25 h
21, resulting in a Tmax between 5
and 30 minutes postdose. The oral bioavailability was cal-
culated with Eq. 5:
Ftotal5 Fa3 Fg3 Fh (5)
where Fa is the fraction absorbed, which is assumed 1 for
midazolam,10 Fg is the gut wall bioavailability, equal to 1
minus Eg, and Fh is the hepatic bioavailability, and Fh5 1 –
Eh.
The fraction unbound in blood for both midazolam and 1-
OH-midazolam in blood was calculated based on the for-
mula of McNamara and Alcorn6:
fu;B;pediatric5
1
11
12fu;B;adultð Þ3 P½ pediatric
P½ adult3fu;B;adult
(6)
where fu,pediatric and fu,adult are the fraction unbound of the
drug in blood for preterm neonates and adults, respectively,
and [P]pediatric and [P]adult are the plasma albumin concen-
trations in preterm neonates and adults, respectively. These
albumin concentrations are calculated based on an age-
based formula from Johnson et al.5 (Table 1) and the frac-
tions unbound of midazolam and 1-OH-midazolam in adults
were reported in literature.28,29 The fraction unbound in
blood and hematocrit were used to calculate the blood:
plasma ratios for midazolam and 1-OH-midazolam using
the formula of Maharaj et al.30:
B : P ratio5 11 Hem3 fu;B3 Kp21ð Þ½  (7)
where B:P ratio is the blood:plasma ratio, Hem is the
hematocrit in preterm neonates (45%),31 fu,B is the fraction
unbound in the blood, and Kp is the unbound partition coef-
ficient of red blood cells (assumed to be constant between
adults and children).30
Total plasma clearance by the liver was calculated based
on33:
CLplasma5
Qh3fu3CLh;int
Qh1 fu3CLh;int= B : P ratioð Þ
  (8)
Figure 1 Schematic representation of the model for midazolam and the 1-OH-midazolam metabolite. CLint, the intrinsic clearance in
the blood; E, extraction ratio; F, bioavailability in the gut wall (gut, G) and the liver (hepatic, H); Ka indicates the absorption rate con-
stant and the fraction unbound in blood and gut wall are described with fu,B and fu,G, respectively. Blood flows are represented by Q; in
the micro villi (Qvilli), portal vein (QPV), hepatic artery (QHA), and the hepatic blood flow (Qh). Parameters relating to the metabolite are
indicated with subscript M. Intrinsic gut wall (CLG,int) and intrinsic hepatic clearance (CLH,int and CLH,int,M), as well as volume of distribu-
tion (for midazolam and 1-OH-midazolam), values were estimated in the model. Total plasma clearance of midazolam was derived
using Eq. 8, and the bioavailability in the gut wall (Fg), liver (Fh), and the total oral bioavailability (Ftotal) were derived based on Eqs. 1,
2, and 5.
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in which Qh is the hepatic blood flow, fu the fraction
unbound in plasma, and CLh,int the intrinsic hepatic
clearance.
To evaluate the structural identifiability or our nonlinear
model, we used the Differential Algebra for Identifiability of
Systems software.34
Table 1 Parameter values for physiological and drug specific parameters in the model
Parameter definition
(unit) Parameter
Formula for
calculation Value References
Tissue volumes (L)
Liver Vh Vh,3.55kg neonate 3
(WT/3.55)
(7)
Vh,3.55kg neonate5 0.120
Portal vein Vpv Vpv50.778 3 Vh (24)
Gut Vgw Vgw,3.55kg neonate 3
(WT/3.55)
(7)
Vgw,3.55kg neonate50.050
Tissue blood flows (L/h)
Hepatic blood flow Qh Qh,3.55kg neonate 3
(WT/3.55)0.75
(7)
Qh,3.55kg neonate5 13.2
Portal vein Qpv 0.75 3 Qh (5, 32)
Hepatic artery Qha 0.25 3 Qh (5, 32)
Small intestine Qin 0.4 3 Qh (25)
Mucosa Qmuc 0.8 3 Qin (25)
Microvilli Qvilli 0.6 3 Qmuc (25)
Plasma proteins
Plasma albumin
concentration (g/L)
[P]pediatric 1.1287 3
ln(Age[yr])1 33.746
27.1 (5)
[P]adult 37.0
Hematocrit (%) Hem – 0.45 (31)
Intestinal surface area and
permeability
Intestinal surface area
(dm2)
A 2p 3 r 3 h 5.97 r: (26)
With radius r5 1 cm and
length
h52.7363(WT[g])0.512 cm
h: (27)
Permeability through the
enterocyte (L/h)
CLperm CLperm5Peff,man [dm/h] 3
A [dm2]
0.95 (25)
Midazolam
Fraction absorbed Fa – 1 (10)
Absorption rate constant Ka (h
21) – 10 –
Blood:plasma ratio B:P ratio 11 [Hem 3 (fu,B 3 Kp21)]
Kp5 1
0.568 (30)
Fraction unbound in gut Fu,G – 1 (25)
Fraction unbound in blood Fu,B
1
11
12fu;adultð Þ3 P½ pediatric
P½ adult3fu;adult
0.04094 (6)
Fu,adult 0.0303 (28)
Effective intestinal
permeability per unit
surface area (cm/s)
Peff,man – 4.4 3 10
24 (25)
1-OH-midazolam
Fraction midazolam
metabolized into 1-OH-
midazolam
fM – 1 –
Blood:plasma ratio B:P ratio 11 [Hem 3 (fu,M 3 Kp21)]
Kp5 1
0.613 (30)
Fraction unbound in blood Fu,M
1
11
12fu;M;adultð Þ3 P½ pediatric
P½ adult3fu;M ;adult
0.1394 (6)
fu,M,adult 0.106 (29)
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Statistical model
Interindividual variability was included in the model as a
log-normal distribution:
hi5hTV3e
gi (9)
where hi is individual parameter estimate for individual i,
hTV is the typical value of the parameter in the studied pop-
ulation, and gi is a random variable from a normal distribu-
tion with a mean of zero and estimated variance of x2.
Residual unexplained variability was modeled using a
combined error model. The jth observed concentration (Y)
of the ith individual was modeled according to:
Yij5Cpred; ij3 11E1ijð Þ1 E2ij (10)
where Cpred,ij is the jth predicted midazolam concentration
of the ith individual, E1ij and E2ij are random variables from
normal distributions with a mean of zero and estimated var-
iance of r2, representing the proportional and additive com-
ponent of the error model, respectively.
Covariate analysis
A covariate analysis on the clearance and volume parame-
ters was performed in which the following covariates were
tested for statistical significance: body weight at birth, ges-
tational age, gender, and mechanical respiratory support,
and furthermore body weight, postmenstrual age, and post-
natal age per occasion (e.g., at the day of dose administra-
tion). There was no missing covariate information for any
subject.
For categorical covariates, separate typical values (hTV)
for the two populations were estimated. Continuous covari-
ates were tested using a linear (Eq. 11) or power (Eq. 12)
function.
hi5hTV3 11hcov3 COV2COVmedð Þð (11)
hi5hTV3
COV
COVmed
 hCOV
(12)
where hi is the individual parameter estimate for the individ-
ual i, hTV is the typical value of the parameter in the studied
population with a median value (COVmed) of the covariate
(COV), and hCOV the estimated slope or exponent for a lin-
ear or power function, respectively.
Model evaluation
Discrimination between different structural models was
made by comparison of the objective function value (OFV;
i.e., 22 3 log-likelihood). A decrease of 3.84 points in the
OFV between nested models was considered statistically
significant (P<0.05). Furthermore, goodness-of-fit plots
(individual-predicted and population-predicted vs. observed
concentrations and conditional weighted residuals vs. time
and population predicted concentrations) of midazolam and
1-OH-midazolam were assessed. In addition, the confi-
dence interval of the parameter estimates and visual
improvement of the individual plots were used to evaluate
the models.
For inclusion of covariates, a decrease in OFV of 6.64
points (P< 0.01) was considered statistically significant,
whereas for the backward deletion a more stringent P
value (P< 0.005; DOFV >7.88) was used. Furthermore, to
retain a covariate in the model, the interindividual variability
in the PK parameter should decrease and in a plot of the
covariate vs. the interindividual variability in the PK param-
eter, the data points should be randomly scattered around
zero.
The model was further internally evaluated using two
different methods, a bootstrap analysis (n5200) and a nor-
malized prediction distribution error analysis (see Supple-
mentary Figures S1 and S2).
Sensitivity analysis
To evaluate the assumptions made in the model, a sensitiv-
ity analysis was performed using simulations in Berkeley
Madonna software (Berkeley Madonna, version 8.3.18).35
Parameter values for tissue volumes and blood flows as
well as intestinal length and the fraction unbound in blood
were increased and decreased by 50% and the impact on
predicted midazolam concentrations was evaluated. Fur-
thermore, the impact of the assumptions on the estimated
PK parameters was assessed by re-estimating the model
with the increased/decreased values for tissue volumes and
blood flows as well as intestinal length and the fraction
unbound in blood.
Dose simulations
To illustrate the impact of first-pass metabolism on midazo-
lam and 1-OH-midazolam exposure in preterm neonates,
model-based simulations of concentration-time profiles
were performed with our model. A dose of 0.1 mg/kg mida-
zolam was simulated as oral administration or as a 30-
minute intravenous infusion in 37 preterm neonates with
the same patient characteristics as the individuals in our
dataset.
RESULTS
Using the physiological population PK model, as depicted
in Figure 1, which was structurally identifiable according to
the Differential Algebra for Identifiability of Systems analy-
sis,34 the PK data in preterm neonates were well described.
Based on the available data, intrinsic CYP3A clearance in
the gut wall and liver were estimated to be 0.0196 (relative
standard error (RSE) 178%) and 6.7 (RSE 10%) L/h,
respectively (Table 2). Distribution volumes for midazolam
and its metabolite in blood were estimated to be 3 (RSE
11%) and 2.7 (RSE 43%) L, respectively, and the addition
of peripheral compartments for either midazolam or 1-OH-
midazolam did not improve the model. No additional covari-
ates could be identified for intrinsic clearance and volume
of distribution. The model was graphically and numerically
evaluated (Table 2, and Supplementary Figures S1 and
S2) and generally the model parameters described the PK
data of both the midazolam and 1-OH-midazolam well. The
additive errors were fixed to very small numbers (Table 2).
Goodness-of-fit plots (Supplementary Figure S1) showed
that the model adequately describes the data, albeit with a
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small overprediction for the low concentrations of midazolam.
In addition, the prediction of the data was unbiased, as
shown in the normalized prediction distribution error analysis
(Supplementary Figure S2), with slightly overpredicted vari-
ability in the metabolite concentrations.
Intrinsic hepatic clearance was much higher and also more
variable than the intrinsic gut wall clearance (Figure 2a).
Figures 2 and 3 show the estimated and derived model
parameters related to the intestinal and hepatic metabolism
in preterm neonates vs. bodyweight. The median total
plasma clearance by the liver was 0.181 L/h (range 0.03–
0.79 L/h; Figure 2b). As both the intrinsic gut wall and
hepatic clearance were found to be very low (Figure 2a), the
extraction ratios were very low for both organs, with a median
of 0.04 in the gut wall (range 0.026–0.046) and a similar
median of 0.04 (range 0.01–0.31) in the liver (Figure 2c).
Based on the extraction ratio in the gut wall and liver, the
fraction escaping gut wall metabolism (Fg) and the fraction
escaping hepatic metabolism (Fh) can be calculated and the
median values are both 0.96. Figure 3 also shows the total
bioavailability for all preterm neonates in our study, as calcu-
lated based on the fraction absorbed (Fa), Fg, and Fh accord-
ing to Eq. 5. A very low first-pass metabolism was observed
with 92% of midazolam entering the systemic circulation in a
typical preterm neonate of 1.1 kg, but the overall range of
percentage entering systemic circulation varies largely
between 67% and 95%. Model-based simulations of plasma
concentration-profiles show limited differences in median
plasma concentrations of midazolam after oral and intrave-
nous administration due to the high bioavailability of 92%
(Figure 4a), whereas the concentrations of 1-OH-midazolam
after oral administration are higher for the first 4 hours post-
dose compared to the 30-minute infusion, due to presystemic
metabolism (Figure 4b).
Table 2 Parameter estimates and bootstrap results of the physiological population PK model
Parameter definition Parameter
Value (RSE%)
[shrinkage %] Bootstrap mediana Bootstrap 90% CI
Midazolam
Intrinsic hepatic clearance CLH,int (L/h) 6.7 (10) 6.6 5.0–8.7
Intrinsic gut wall clearance CLG,int (mL/h) 19.6 (178) 14.0 0.2
b2319
Volume of distribution V (L) 3.0 (11) 3.0 2.4–3.7
1-OH-midazolam
Intrinsic hepatic clearance CLH,int,M (L/h) 8.9 (22) 7.7 3.5–11.2
Volume of distribution VM (L) 2.7 (43) 2.9 1.5–7.2
Interindividual variability (x2)
Intrinsic hepatic clearance x2 CLH,int 0.887 (26) [3] 0.851 0.551–1.16
Intrinsic gut wall clearance x2 CLG,int – – –
Volume of distribution x2 V 0.603 (26) [2] 0.603 0.311–0.857
Intrinsic hepatic clearance 1-OH-midazolam x2 CLH,int,M 0.832 (42) [15] 0.709 0.201–1.65
Volume of distribution 1-OH-midazolam x2 VM 0.887 (48) [8] 1.2 0.442–4.04
Residual variability (r2)
Proportional error (midazolam) 0.201 (26) [10] 0.192 0.134–0.264
Additional error (midazolam) 0.0001 FIX 0.0001 –
Proportional error (1-OH-midazolam) 0.164 (91) [33] 0.155 0.000b20.242
Additional error (1-OH-midazolam) 0.0001 FIX 0.0001 –
CI, confidence interval; PK, pharmacokinetic; RSE, relative standard error.
aBootstrap results based on stratified bootstrap sampling for patients receiving an intravenous, an oral, or twice a dose administration. The median and 90%
confidence interval are calculated based on 37.8% successful runs and runs with estimates near a boundary.
bThe 5% percentile reached the lower boundary of 0.2 mL/h and 0.1*1024, for CLG,int and the proportional error for 1-OH-midazolam, respectively. Interindivid-
ual and residual variability values are shown as variance estimates.
Figure 2 Intrinsic clearance (a), total plasma clearance (Eq. 8) (b) and extraction ratio (c) are plotted vs. body weight, in which values
are given for the gut wall () and the liver ().
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A sensitivity analysis showed that blood concentration pre-
dictions would change <1% for both peak and trough con-
centrations in case the values for tissue volumes and tissue
blood flows were altered with650%. In addition, no signifi-
cant change in parameter estimates was found when the
parameters were re-estimated based on the same changes
in tissue volumes, nor did different ka values impact esti-
mated and derived clearance and bioavailability parameters.
However, an increase of 50% in intestinal and hepatic blood
flow resulted in an increase of 20–30% and 50% in the esti-
mated intrinsic intestinal or hepatic clearance, respectively,
and vice versa without profound changes in extraction ratio
and bioavailability. Changes in intestinal length (which con-
tributes to the flow term in the gut wall (Qgut), that accounts
for the permeability through the enterocyte (CLperm) and the
villous blood flow (Qvi)) did not result in different blood con-
centrations (change <1%), although the re-estimated intrin-
sic clearance in the gut wall changed 118 or 232% for an
increase or decrease in intestinal length, respectively. The
change in fraction unbound in blood for either midazolam or
1-OH-midazolam was inversely correlated with the same
fractional change in estimated hepatic intrinsic clearance.
DISCUSSION
Using a physiological population PK model in which both
physiological information and midazolam and metabolite con-
centrations after oral and intravenous administration were
used, we were able to distinguish between intestinal and
hepatic intrinsic clearance of midazolam in preterm neo-
nates. The PK data used to estimate the CYP3A-mediated
midazolam clearance came from a unique dataset with a
crossover design in which preterm neonates received both
an oral and an intravenous dose, allowing to study both the
first-pass and systemic metabolism. Our physiological popu-
lation PK modeling approach, which has already been
applied in healthy adults,22 was also able to describe the
absorption and disposition of midazolam in preterm neo-
nates. The results show that the CYP3A-mediated intrinsic
gut clearance is much lower than the intrinsic hepatic clear-
ance (Table 2, Figure 2a), whereas in healthy adult volun-
teers this difference is reported to be smaller (ratio of 340
in preterm neonates vs. 60 in adults).22 Although this indi-
cates a difference in maturation of CYP3A activity in the gut
wall and the liver in preterm neonates, both the intestinal
and hepatic extraction ratio of midazolam in preterm neo-
nates were very low (median of 0.04 each). This results in a
very small first-pass effect leading to a high total bioavailabil-
ity of 92.1% (Figure 3) and almost identical concentration-
time profiles after intravenous and oral administration (Fig-
ure 4a) for the CYP3A-substrate midazolam in preterm neo-
nates. For the metabolite, however, an increased plasma
concentration can be observed in the first 4 hours after oral
administration due to the presystemic formation of the
metabolite in both the gut wall and liver (Figure 4b). In
adults, much higher median extraction ratios of 0.59 and
0.34 have been reported for the gut wall and the liver,
respectively,22 resulting in a lower total bioavailability of
around 30% in adults.
The intrinsic gut wall clearance values we obtained in
preterm neonates were found to be lower than the values
reported in adults. Additionally, in preterm neonates, the
intrinsic gut wall clearance was much lower than the intrin-
sic hepatic clearance, and this difference was much larger
in preterm neonates than in adults.22 This could be due to
Figure 3 Bioavailability in the gut (Fg) and liver (Fh), and total
bioavailability (Ftotal) in preterm neonates.
Figure 4 Model-based simulations of midazolam (a) and 1-OH-midazolam (b) pharmacokinetic profiles following a 0.1 mg/kg dose via
an 30-minute infusion (gray lines) or orally (black lines). The solid lines represent the median plasma concentrations and the dashed
lines show the minimal and maximal achieved concentrations of midazolam in the studied population.
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the immaturity of enterocytic CYP3A enzyme activity in this
population.36,37 The activity in the gut wall has been
reported to be lower with decreasing age,37 but also con-
flicting activity values have been reported.36 Besides the
activity, the abundance of the CYP3A enzyme, reflected by
a smaller number of milligrams of microsomal protein per
gram of intestine,37 as well as the smaller intestinal surface
area led to a lower total intestinal CYP3A activity in preterm
neonates compared with adults. The smaller surface area
was calculated in our study based on intestinal length (70–
157 cm for infants with a postconceptional age of 24–40
weeks without gastrointestinal malformations undergoing
laparotomy,27 which is in agreement with other litera-
ture38,39 and on the mean intestinal radius of 1 cm.26 A
sensitivity analysis showed that with a decreased intestinal
length, both the flow term that accounts for villous blood
flow and permeability (Qgut) and the gut wall clearance
(CLG,int) decreased, resulting in the same reported extrac-
tion ratio of 0.04. Furthermore, preterm infants have an
underdeveloped intestinal barrier,15 and neonates with a
gestational age <34 weeks have a higher intestinal perme-
ability,16 which could be due to differences in the intracellu-
lar structures that regulate the intestinal permeability.40 In
our model, the permeability factor CLperm
25 accounts for
the intestinal surface area and the permeability of the intes-
tinal barrier in preterm neonates. Food in the gastrointesti-
nal tract may alter the gastrointestinal physiology, including
the motility patterns, intestinal transit time, and the local
blood flow,41 but was not accounted for in our model
because the exact times of parenteral and enteral feeding
were not recorded during the study.
The intrinsic hepatic clearance obtained in our study in
preterm neonates was very low compared with reported
values in healthy adults (6.7 L/h and 1,620 L/h in preterm
neonates and adults, respectively).22 The neonatal liver is
relatively immature shortly after birth, and its functional
capacity in bile synthesis, detoxification, and metabolism
increases during the early postnatal period.42 Fetal and
neonatal livers have different bile acid synthetic pathways
than adult livers, and the bile acid pool is reduced,42 limiting
the probability of biliary excretion and enterohepatic recircu-
lation of drugs in preterm neonates. The maturation of liver
function is not a linear process, as the drug metabolizing
enzyme expression changes nonlinearly during develop-
ment.3 In the fetal liver, 30–60% of adult values in cyto-
chrome P450 content is found and the total hepatic CYP
content increases after birth.43 Of these CYP enzymes, the
CYP3A family is the most abundant.8,13,44 The CYP3A iso-
forms show a different ontogeny profile, with CYP3A4 activity
increasing in preterm neonates with increasing age, CYP3A5
activity seems to be stable from neonatal life to adulthood,
whereas simultaneously CYP3A7 activity declines in neo-
nates.44 Within the group of preterm neonates included in
this study,19,20 we could not identify a trend in hepatic intrin-
sic clearance with gestational age or postnatal age, which
can be explained by the small age range of the studied pop-
ulation. Due to the lower intrinsic hepatic clearance, the
hepatic extraction ratio is very low in preterm neonates com-
pared with adults, resulting in a much higher hepatic bioavail-
ability than expected based on adult values. This has been
previously reported by Salem et al.45 who found that the
hepatic extraction ratio of midazolam increased with age.
They found that the ontogeny of hepatic enzyme abundance
and to a lesser extent the smaller number of microsomal pro-
tein per gram of liver contributed to the observed differences
between preterm neonates and adults.45 Based on the
hepatic intrinsic clearance, the hepatic blood flow, the frac-
tion unbound in blood, and the blood:plasma ratio, the total
plasma clearance can be calculated (Eq. 8). The plasma
clearance ranged from 0.03 to 0.79 L/h with a median value
of 0.181 L/h (Figure 2b). This is in agreement with other
reported values of 3.9 mL/min (0.23 L/h) for preterm neo-
nates with a mean gestational age of 32.16 2.8 weeks12
and higher than the reported values of 0.783 mL/min
(0.05 L/h) and 0.104 L/h in very premature neonates with a
mean gestational age of 27 (24–31) and 27.9 (25–30)
weeks, respectively.46,47
The RSE percentage for the estimated intrinsic gut wall
clearance value and high range of the 90% bootstrap confi-
dence interval of this parameter together with a high num-
ber of unsuccessful runs in the bootstrap and a high
condition number suggest overparameterization of the
model. In a population modeling approach, this could war-
rant a re-evaluation of the structural model, however, our
structural model and a subset of parameter values are
based on physiological knowledge and physiologically
based pharmacokinetic principles, and only the values of
the remaining subset of parameters were estimated from
concentration-time data using population modeling princi-
ples. The high RSE% and 90% bootstrap confidence inter-
val can, therefore, be interpreted to mean that the data do
not support a very precise estimate of intrinsic gut wall
clearance.
For the structural model a few assumptions were
included, which were evaluated in a sensitivity analysis.
Plasma albumin concentrations were calculated based on a
reported age-based formula by Johnson et al.5 in term neo-
nates, assuming the preterm neonates to have the same
concentrations as a 1-day-old term neonate. In addition,
only plasma albumin concentrations were taken into
account. Free fatty acid (FFA) concentrations are known to
reduce protein binding of diazepam in neonates,48 and
could result in a higher fraction unbound in blood for mida-
zolam as well, but this was not taken into account, nor
were other factors that could impact protein binding of mid-
azolam. Our findings about the low gut wall and hepatic
extraction leading to a small first-pass effect and high bio-
availability in preterm neonates are, however, not influenced
by these assumptions. Even though the fraction unbound
and the intrinsic hepatic clearances are related, a different
fraction unbound would increase the intrinsic clearance pro-
portionally, yielding no net changes in extraction ratio or
bioavailability. Furthermore, tissue volumes and organ blood
flows are not directly measurable in preterm neonates.
Therefore, allometric scaling was applied to scale the organ
blood flows from data in term neonates7 to preterm neo-
nates. The sensitivity analysis showed that changes in
assumed organ blood flow are correlated with the estimated
organ clearances: with an increased intestinal blood flow,
the intrinsic intestinal clearance was estimated higher and
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the assumptions of the hepatic blood flow were found to
correlate with the estimated intrinsic hepatic clearance.
However, in this study, also the extraction ratios and bio-
availability derived from the estimated parameter values
remained unaffected by changes in organ blood flows and
would, therefore, not have an impact on our finding that the
first-pass midazolam in preterm neonates is much smaller
than in adults.
To conclude, the developed physiological population PK
model was able to distinguish between CYP3A-mediated
intestinal and hepatic metabolism of midazolam in preterm
neonates. Intrinsic clearance in the gut wall was much
lower than in the liver, but the median intestinal and hepatic
bioavailability were both very high. This indicates a very low
first-pass effect by intestinal and hepatic CYP3A-mediated
metabolism in preterm neonates compared with adults. Fur-
thermore, the variability in bioavailability was very high, indi-
cating that oral dosing may yield large differences in drug
exposure within this population. Overall, the PK of midazo-
lam and its primary metabolite 1-OH-midazolam were well-
described by the model, and this physiological model may,
therefore, be used to predict the first-pass effect and sys-
temic metabolism of midazolam and other orally adminis-
tered CYP3A substrates in preterm neonates based on the
physiological and drug properties.
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